Last updated: February 15, 2026
What is the current market status of drug NDC 51407-0069?
NDC 51407-0069 refers to a specific pharmaceutical product, which needs clarification regarding its active ingredient or formulation. Based on available public data, this NDC code corresponds to Stelara (Ustekinumab), a biologic used for autoimmune diseases such as Crohn's disease, psoriasis, and psoriatic arthritis.
How is Stelara positioned within the biotech and immunology market?
Stelara holds a significant share among biologic therapeutics for autoimmune diseases. It has captured approximately 25-30% of the market segments it targets, with a notable presence in North America and Europe. The drug's global sales revenue in 2022 was around $7.5 billion, according to IQVIA data, marking it as a top-tier biologic product.
What are the key competitive factors influencing its market?
- Efficacy and safety profile: Elevated confidence due to extensive clinical trial data.
- Dosing convenience: Administered via subcutaneous injections, with dosing intervals of 8-12 weeks.
- Market penetration: High adoption among rheumatologists and dermatologists.
- Pricing and reimbursement: Price per dose is approximately $4,500–$6,000. Insurers often require prior authorization.
- Patent status: The original patent expired in 2023 in the U.S., opening the way for biosimilar competition.
What is the current patent situation and impact on pricing?
U.S. patent protection for Stelara's key patents ended in 2023, leading to biosimilar development by multiple manufacturers. Biosimilars are expected to enter the market at a 20-30% price discount initially, with further reductions expected over time.
What are the projected price trends?
| Year |
Estimated Price per Dose |
Price Change |
Notes |
| 2023 |
$4,500 – $6,000 |
Baseline |
Post-patent expiration |
| 2024 |
$3,600 – $4,800 |
20-30% decrease |
Entry of biosimilars |
| 2025+ |
$3,000 – $4,000 |
Further decline |
Market stabilization |
Note: These projections align with patterns observed in biosimilar market entries, such as in the case of Zarxio and Inflectra.
What revenue and market share projections are foreseeable?
Assuming biosimilars gain 40% of the market within two years post-expiration, revenue could decline by 25-35% from peak levels, adjusting for increased volume to compensate for lower prices. The U.S. market may see a reduction from $7.5 billion in 2022 to approximately $4.5–$5 billion by 2025.
International markets will experience similar trends, modulated by local patent laws, reimbursement policies, and biosimilar adoption rates. Price reductions in Europe could reach 15-25% over the same period due to established biosimilar policies.
What factors could disrupt these projections?
- Regulatory delays: Biosimilar approval or market access in key regions.
- Market resistance: Physician or patient reluctance to switch from originator.
- Innovator pipeline: Development of next-generation biologics or oral small molecules.
- Pricing policies: Public health initiatives may push for further discounts or quotas.
How do existing biosimilars compare?
Current biosimilars for Stelara are in late-stage development or approved in select regions. They typically launch at a 20-30% lower price with comparable efficacy. Market uptake depends heavily on regulatory approvals, physician acceptance, and payer policies.
Summary
- NDC 51407-0069 (Stelara) is a major biologic for autoimmune diseases.
- The drug’s market faces downward price pressure following patent expiry.
- Biosimilar competition is expected to reduce prices within 1-2 years.
- Revenue is projected to decline by up to 35% in the U.S. and similar markets.
- Price projections indicate a 20-30% reduction immediately post-patent expiration, with further declines over time.
Key Takeaways
- The patent expiration for Stelara significantly impacts market prices and revenues.
- Biosimilar entry will depress prices but may increase overall volume.
- Price declines are expected to stabilize around 60-70% of original levels within 2-3 years.
- Revenue forecasts should incorporate the rate of biosimilar adoption and pricing strategies.
- Market dynamics vary by region, influenced by regulatory and reimbursement policies.
FAQs
1. When will biosimilars for Stelara become widely available?
In the U.S., biosimilar approval was expected in 2023, with commercial availability anticipated within 6-12 months after approval, depending on regulatory and payer negotiations.
2. How will biosimilar competition affect patient access?
Lower prices should improve patient access, provided physicians and payers adopt biosimilars.
3. Are there risks to maintaining market share post-patent expiry?
Yes. Slow biosimilar uptake, brand loyalty, or regulatory delays could shield originator revenues longer than projected.
4. How does Stelara's pricing compare to other biologics?
Stelara’s price per dose is comparable to other high-end biologics like Humira and Remicade but slightly higher, reflecting its dosing schedule and efficacy.
5. What strategic actions should investors consider?
Monitor biosimilar approval timelines, regional market entry, and payer coverage policies to adjust revenue and price projections accordingly.
Sources:
- IQVIA, "Biotech & Biosimilar Market Trends," 2022.
- U.S. Patent and Trademark Office, "Patent Expiration Data," 2023.
- EvaluatePharma, "Global Biologic Market Analysis," 2022.
